Investigating the prognostic impact of NY-ESO-1 expression and HLA subtypes in metastatic synovial sarcoma
Article 2024 en
Authors
AD
A. Dufresne
SP
Shibani Pokras
AM
A. Meurgey
Abstract
1 min read
The primary tumor cohort showed no association between NY-ESO-1 expression and OS (including stratification by HLA-A∗02 subtype and treatment line) when adjusting for important prognostic factors, possibly due to small sample sizes.
Sandra P. D’Angelo, Vivek Subbiah, Jean Yves Blay, Michael J. Wagner, Neeltje Steeghs, Jeonghwan Youk, Hideki Mizusako, Yoshihiro Ohue, Jin Jin, Abdul Waheed Rajper, Nicole Tesar, Patrick Schöffski
Brian Andrew Van Tine, Kristen N. Ganjoo, Jean Yves Blay, Claudia Valverde, Dejka M. Araujo, Albiruni Ryan Abdul Razak, Axel Le Cesne, Scott M. Schuetze, Michael J. Wagner, Steven Attia, Édouard Forcade, Mihaela Druta, Seth M. Pollack, Jane P. F. Bai, Peter Bayer, Erin Van Winkle, Elliot Norry, Cheryl McAlpine, Dennis Williams, Sandra P. D’Angelo
Hélène Vanacker, Robert Connacher, Alexandra Meurgey, Julien Bollard, Valéry Attignon, Franck Tirode, Myriam Jean‐Denis, Mehdi Brahmi, Jean Yves Blay, Ruoxi Wang, Dennis Williams, Armelle Dufresne
Jonathan Cebon, Šárka Svobodová, Jeffrey L. Browning, Ian D. Davis, Richard A Scolyer, Ramachandran Murali, John F. Thompson, Sumitra Deb, A. Azad, Duncan MacGregor
Discussion(0)
No comments yet. Be the first to comment.